Itasca MGA Provides Aircraft Finance Insurance Cover to Allegiant Air
"The Itasca team is happy to provide a customized insurance solution to Allegiant as it seeks to expand its fleet with additional Boeing MAX aircraft," said
The aircraft deliveries are part of Allegiant's announced strategy to directly own its fleet, enabling it to adapt quickly to changing economic conditions and enhance its fleet economics.
"We are excited to add these brand-new 737 MAX 8-200 aircraft to our fleet with the support of Itasca's competitive insurance solution, supporting our overall cost of ownership," said Allegiant CFO
"Recognizing the need for customized solutions in a highly competitive aviation financing market, we established Itasca with Pine Walk Capital to offer tailored insurance financing to buyers and owners of commercial aircraft assets," said
The aircraft are expected to be delivered by the third quarter of 2025.
About Itasca MGA
Itasca MGA is a managing general agent housed within the Pine Walk Group that specializes in underwriting, structuring and managing risk associated with secured commercial aviation financing on behalf of The Fidelis Partnership and Itasca Re Limited, a Bermuda-licensed reinsurance company established by Castlelake that specializes in insurance-backed financing solutions for buyers and owners of commercial aircraft assets. To support airline and lessor customers, Itasca MGA uses insurance capacity provided by Fidelis Insurance Ireland DAC, Fidelis Underwriting Limited and Lloyd's Syndicate 3123, alongside Starr Europe Insurance Limited and Starr Europe Insurance Limited with the latter two reinsured by Itasca Re. For more information, visit https://www.itascare.com/.
Media contact:
Itasca MGA
+1 612 851 3000
View original content to download multimedia:https://www.prnewswire.com/news-releases/itasca-mga-provides-aircraft-finance-insurance-cover-to-allegiant-air-302517370.html
SOURCE Itasca MGA
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Akeso's AK157D1 (B7-H3 ADC) Cleared for Phase I Trial in Solid Tumors, Adding a Third Differentiated ADC to Its Pipeline
- Global Times: How wish walls are powering China's trillion‑yuan silver economy
- Implantica receives FDA approval for RefluxStop® - Opening the U.S. market
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share